-
Wnt-C59 as a Causal Probe of Wnt10a Secretion
2026-08-18
Wnt-C59 is a potent PORCN inhibitor for testing whether exosomal Wnt10a secretion causally drives β-catenin-dependent osteogenesis. This article translates recent BMSC findings into a rigorous assay strategy while defining implications for cancer biology.
-
DiscoveryProbe Natural Product Library Plus Workflow
2026-08-18
Turn a chemically diverse natural product library into a staged workflow for enzyme inhibition, parasite phenotyping, and pathway-level validation. This practical guide combines the DiscoveryProbe Natural Product Library Plus with lessons from recent CpAdhE research to improve hit triage, reproducibility, and troubleshooting.
-
Flubendazole as an Autophagy Assay Lens
2026-08-17
Flubendazole can serve as a controlled perturbation for testing how autophagy intersects with tumor-microenvironment signaling. This article translates breast cancer extracellular-vesicle findings into a rigorous assay framework without confusing an autophagy tool with a validated treatment mechanism.
-
P2RX1, Calcium, and Mitochondrial Apoptosis in Ph+ ALL
2026-08-17
This 2025 study identifies P2RX1 as a regulator of tyrosine kinase inhibitor sensitivity in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking purinergic signaling to calcium imbalance, CaMKII activation, PI3K/Akt suppression, and mitochondrial apoptosis. Its findings provide a mechanistic framework for interpreting cell-death responses in Ph+ ALL models while highlighting the need for validation beyond a single engineered cell line.
-
VX-661 and the Next Era of CFTR Rescue
2026-08-16
VX-661 offers more than a folding-rescue readout. By linking F508del CFTR correction to calnexin-dependent proteostasis, variant-aware phenotyping, and exposure sequencing, translational teams can build more predictive cystic fibrosis workflows.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-08-15
The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney disease, linking its activity to renal fibrosis, inflammation, epithelial–mesenchymal transition, and Smad3/STAT3 signaling. By testing two SMYD2-directed compounds in animal and tubular epithelial cell models, the work provides a mechanistic framework for evaluating epigenetic intervention in treatment-associated kidney injury.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-08-14
The Phenomics protocol by Zhao and colleagues establishes a standardized whole-blood platform for testing how metabolic interventions alter stimulus-specific immune responses. Its main contribution is the integration of controlled immune stimulation, pathway-directed metabolic modulation, and cytokine quantification in fresh human blood, creating a practical framework for reproducible cohort studies.
-
Chemerin–cNTS Signaling Raises Sympathetic Activity
2026-08-14
Hao and colleagues show that chemerin signaling in the caudal nucleus tractus solitarius increases renal sympathetic nerve activity, arterial pressure, and heart rate through CMKLR1-dependent NADPH oxidase activation and superoxide production. Pharmacological pathway testing further implicates NMDA, rather than AMPA/kainate, receptor transmission in the downstream paraventricular nucleus, clarifying how an adipokine can influence central cardiovascular control.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Guide
2026-08-13
Build a dual-readout mRNA delivery assay that separates cellular uptake from productive translation. EZ Cap™ Cy5 EGFP mRNA (5-moUTP) combines direct Cy5 tracking with EGFP expression for nanoparticle validation, macrophage targeting, and faster troubleshooting.
-
FH1 for iPS-Derived Hepatocyte Maturation
2026-08-13
FH1 is a practical small-molecule option for improving functional readouts during iPS cell differentiation to hepatocytes, with reported gains in albumin secretion, CYP3A4, colony morphology, and reduced AFP. This guide translates those findings into a controlled iHep workflow and shows how the reference study’s light-regulated translation strategy can inform, but not replace, FH1 assay design.
-
Balsalazide disodium: Workflows for IBD Research
2026-08-12
Balsalazide disodium supports colon-focused inflammation research, from water-based assay preparation to radiolabeled imaging in ulcerative colitis models. Its practical differentiation is the combination of a 5-aminosalicylic acid prodrug design, aqueous solubility, and a reference workflow that achieved high ulcerated-colon uptake in mice.
-
Torin2: Separating mTOR Signaling From Cell Death
2026-08-12
Torin2 is a potent mTOR inhibitor for dissecting pathway suppression, transcriptional stress, and apoptosis without conflating these outcomes. This interpretation-first guide connects recent Pol II findings with practical assay design and medullary thyroid carcinoma research.
-
Phosphotungstic Acid Negative Stain: Form to Function
2026-08-11
Phosphotungstic Acid Negative Stain Solution (2%) is more than an electron microscopy stain: it is a practical morphology checkpoint for virology and macromolecular research. This guide explains how to interpret structural evidence alongside mechanistic assays, using conserved coronavirus spike glycans as a scientifically grounded example.
-
Wnt-C59 Workflows for PORCN Inhibition
2026-08-11
Wnt-C59 provides a high-potency route to test whether Wnt-ligand secretion drives a phenotype, from cholangiocarcinoma growth assays to exosome-mediated osteogenesis. This practical guide connects PORCN inhibition with dose design, Wnt/β-catenin readouts, donor–recipient exosome experiments, and troubleshooting.
-
DOT1L Inhibition Potentiates Lenalidomide in Myeloma
2026-08-10
A 2025 Cancer Letters study shows that DOT1L inhibition reprograms type I interferon and STING-associated innate immune signaling in multiple myeloma cells while suppressing IRF4-MYC activity. The work provides a mechanistic rationale for combining epigenetic intervention with lenalidomide, although validation beyond cell-line and dependency-dataset evidence remains necessary.